Physician profile
John C Lee
NPI 1104813427
$9,760.63
in general payments reported to CMS, 2019-2025
30 companies · $1,464 in 2025
The $1,464 reported for 2025 was more than what 86% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,505 · 2020: $507 · 2021: $1,700 · 2022: $1,232 · 2023: $1,889 · 2024: $1,463 · 2025: $1,464.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,739 · Education: $77.51.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,738.90 |
| Education | $77.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,278.28 | 2021-2025 | |
| Otsuka America Pharmaceutical, INC. | $1,145.90 | 2019-2025 | Rexulti, Nuedexta |
| Takeda Pharmaceuticals U.S.A., INC. | $1,116.01 | 2019-2025 | Trintellix |
| Sunovion Pharmaceuticals INC. | $934.91 | 2019-2022 | |
| Alkermes, INC. | $783.70 | 2022-2025 | Aristada, Lybalvi |
| Corium, LLC | $730.35 | 2022-2025 | Azstarys |
| Lundbeck LLC | $601.19 | 2019-2025 | Rexulti |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $548.51 | 2021-2025 | Caplyta |
| Neurocrine Biosciences, INC. | $374.31 | 2019-2025 | Ingrezza |
| Janssen Pharmaceuticals, INC | $300.23 | 2019-2025 | Spravato, Invega Sustenna, Invega Trinza |
| Supernus Pharmaceuticals, INC. | $255.03 | 2021-2025 | Qelbree, Qelbree |
| Allergan, INC. | $242.13 | 2019-2020 | |
| Axsome Therapeutics, INC. | $196.90 | 2022-2024 | Auvelity |
| Ironshore Pharmaceuticals INC. | $194.35 | 2019-2024 | Jornay Pm |
| Collegium Pharmaceutical, INC. | $161.59 | 2025 | Jornay Pm |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neos Therapeutics, Lp | $113.83 | 2019-2025 | Adzenys Xr-Odt |
| Avanir Pharmaceuticals, INC. | $113.60 | 2019-2022 | |
| Teva Pharmaceuticals USA, INC. | $97.03 | 2019-2024 | Uzedy |
| E.R. Squibb & Sons, L.L.C. | $81.67 | 2024-2025 | Cobenfy |
| Shire North American Group INC | $79.61 | 2019 | |
| Tris Pharma INC | $78.73 | 2019-2022 | |
| Jazz Pharmaceuticals INC. | $71.52 | 2019-2021 | |
| Vertical Pharmaceuticals, LLC | $70.36 | 2019 | |
| Idorsia Pharmaceuticals US INC | $51.66 | 2022-2023 | Quviviq |
| Bausch Health US, LLC | $45.14 | 2019-2020 | |
| Vanda Pharmaceuticals INC. | $28.98 | 2019 | |
| Eisai INC. | $24.39 | 2021 | |
| Biogen, INC. | $16.09 | 2024 | |
| Arbor Pharmaceuticals, INC. | $13.36 | 2019 | |
| Adlon Therapeutics L.P. | $11.27 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Lee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.